| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6183009 | Gynecologic Oncology | 2016 | 9 Pages |
Abstract
The combined use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib may be effective in ovarian cancers with a broader spectrum of cancer-associated genetic alterations but not limited to those with mutant PIK3CA or BRCA genes. BRCA downregulation may be a potential biomarker for the effective response to the proposed combination treatment.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Dong Wang, Chengbo Li, Yuan Zhang, Min Wang, Nan Jiang, Lin Xiang, Ting Li, Thomas M. Roberts, Jean J. Zhao, Hailing Cheng, Pixu Liu,